Abbott Volt PFA shows strong 12‑month efficacy, safety in global real‑world study
- Abbott Laboratories reports VOLT‑AF IDE 12‑month results: 84.2% freedom from recurrence in paroxysmal AF.
- Abbott presents TactiFlex Duo 12‑month CE‑Mark results showing safety and reduced AF episodes in complex cases.
- Abbott says combined results support wider adoption, registry follow‑up, potential label expansions and continued investment.
Volt PFA posts strong 12-month outcomes in global real‑world study
Abbott Laboratories is reporting 12‑month data from its multi‑center VOLT‑AF Global IDE study that reinforce the safety and efficacy of its Volt Pulsed Field Ablation (PFA) System for treating atrial fibrillation (AF). The single‑arm study, spanning roughly 40 centers across the United States, Europe, Canada and Australia, shows an industry‑leading 84.2% freedom from documented rhythm recurrence for paroxysmal AF and about 67.9% for persistent AF at one year. Physicians use an average of 4.6 applications per vein, and fewer than 6% of patients require repeat ablation, indicating a reduced procedural burden compared with many historical benchmarks.
Patient‑reported outcomes in the VOLT‑AF study demonstrate substantial quality‑of‑life gains on the AFEQT instrument, with scores improving from 63.6 to 91.4 for paroxysmal AF and from 64.2 to 91.4 for persistent AF. Safety signals are notable: the trial reports no complications related to esophageal injury or hemolysis at 12 months. Abbott emphasizes that the IDE study captures both objective rhythm outcomes and patient‑reported measures in a broad, routine‑practice population, underscoring the device’s performance outside highly controlled investigational settings.
Investigators and Abbott frame the results as evidence of durable clinical performance for Volt PFA, saying the combination of high freedom from recurrence, low repeat‑procedure rates and strong quality‑of‑life improvements position the technology as an effective, efficient option for electrophysiologists. The findings are presented at the AF Symposium in Boston and accompany a simultaneous publication in JACC: Clinical Electrophysiology, supporting ongoing clinical adoption and further evaluation.
TactiFlex Duo focal catheter shows clinical benefit
Separately, Abbott presents 12‑month results from the CE Mark FOCALFLEX trial for its dual‑energy, focal TactiFlex Duo Ablation Catheter, Sensor Enabled. The data highlight the catheter’s sensor‑enabled design that lets operators tailor energy delivery to patient anatomy and electrophysiology, demonstrating safety and efficacy in more complex AF cases and significant reductions in AF episodes.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

